Matinas BioPharma Announces Publication of Results from the Phase 2 EnACT Clinical Trial of MAT2203 in the IDSA Journal Clinical Infectious Diseases
BEDMINSTER, N.J., Aug. 22, 2023 -- Matinas BioPharma , a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal platform delivery...
United States Matinas Biopharma Theresa Matkovits David Boulware Jody Cain National Institutes Of Health
Source: marketscreener.com